Outlook Therapeutics, Inc. (OTLK)
Health Care · Ophthalmic Biologics / Retinal Therapeutics · Nasdaq
Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA review in the US for wet AMD treatment.
What Outlook Therapeutics, Inc. does
Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ophthalmic treatments for retinal diseases. The company's lead product is ONS-5010/LYTENAVA (bevacizumab gamma), an ophthalmic formulation of bevacizumab currently approved and commercially available in Germany and the United Kingdom for wet age-related macular degeneration (wet AMD), with a Biologics License Application under FDA review in the United States. The company is pursuing regulatory approval and commercialization in additional markets while managing manufacturing and distribution capabilities.
Themes: ["wet age-related macular degeneration (wet AMD)","retinal disease treatment","ophthalmic biologics","FDA regulatory approval"]
Fundamentals
- Price$1.57 as of 2026-07-10 close
- Market cap$251M as of 2026-07-13
- 1-year return-22.3% as of 2026-07-10 close
- Net margin-1507.0% as of 2026-07-13
- Gross margin+4.0% as of 2026-07-13
- ROE-415.5% as of 2026-07-13
- Debt / equity3.04 as of 2026-07-13
- Revenue growth (YoY)-22.9% as of 2026-07-13
- Beta0.73 as of 2026-07-13
Key risks (from latest filing)
["Regulatory risk: Inability to obtain and maintain FDA approval for ONS-5010/LYTENAVA in the United States and other markets","Commercialization risk: Failure to successfully commercialize LYTENAVA in the UK and EU markets and achieve market acceptance among physicians and patients","Funding risk: Insufficient cash resources and working capital to meet operational needs without additional financing"]
Competitors & peers
- Regeneron Pharmaceuticals (REGN) - Eylea (aflibercept)
- Roche/Genentech - Avastin (bevacizumab)
- Novartis - Beovu (brolucizumab)
- Bausch Health - Retisert (fluocinolone acetonide)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.